Project description:Acute myeloid leukemia (AML) is a heterogeneous disease in respect of molecular aberrations and prognosis. We used gene expression profiling of 562 patients treated in the German AMLCG 1999 trial to develop a gene signature that predicts survival in AML. Analysis of 562 samples (140 HGU-133plus2; 422 HGU-133A; 422 HGU-133B) from adult patients with acute myeloid leukemia (AML).
Project description:We have performed a comprehensive proteomic analysis of clinical patient samples of acute myeloid leukemia (AML) alongside genome-, transcriptome- and ex-vivo drug response profiling.
